Markets

NPS Pharmaceuticals (NPSP) in Focus: Stock Rises 13.4% - Tale of the Tape

NPS Pharmaceuticals, Inc. ( NPSP ) was a big mover last session with its shares rising over 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company as the stock is now trading way above the past one month's volatile price range of $24.17 to $28.64.

This biopharmaceutical company has seen 8 negative estimate revisions in the last 30 days. The Zacks Consensus Estimate has also moved lower over the same time frame. This implies trouble down the road. So make sure to keep an eye on this stock going forward to see if Friday's rally can last.

NPS Pharmaceuticals currently has a Zacks Rank #5 (Strong Sell) while its Earnings ESP is 0.00%.

Investors interested in the Med-Drugs industry may consider better-ranked stocks like Ariad Pharmaceuticals Inc. ( ARIA ), Avanir Pharmaceuticals, Inc. ( AVNR ) and Aeolus Pharmaceuticals Inc. ( AOLS ). All the three stocks carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

NPS PHARMA INC (NPSP): Free Stock Analysis Report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

AVANIR PHARM (AVNR): Free Stock Analysis Report

AEOLUS PHARMACT (AOLS): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AOLS

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More